Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7893833 | 0.84 | DYRK1A (0.54) | DYRK1APRNPHTTALDH1A1MAPT | |
| SCHEMBL2440682 | 0.83 | GSK3B (0.41) | DYRK1APRNPHTTALDH1A1MAPT | |
| SCHEMBL3309178 | 0.83 | CA12 (0.42) | DYRK1APRNPHTTALDH1A1MAPT | |
| SCHEMBL2144813 | 0.82 | PRNP (0.44) | DYRK1APRNPHTTALDH1A1RXFP1 | |
| SCHEMBL2440209 | 0.81 | SMN1; SMN2 (0.51) | PRNPALDH1A1MAPTPOLBTP53 | |
| SCHEMBL2438375 | 0.80 | SMN1; SMN2 (0.57) | MAPTKDM4EL3MBTL1TP53SMN1; SMN2 | |
| SCHEMBL19793140 | 0.77 | SCD5 (0.46) | PRNPHTTALDH1A1MAPTKDM4E | |
| SCHEMBL19793163 | 0.76 | ALDH1A1 (0.36) | PRNPHTTALDH1A1RXFP1MAPT | |
| SCHEMBL2440215 | 0.76 | PRNP (0.41) | DYRK1APRNPHTTALDH1A1RXFP1 | |
| SCHEMBL26633206 | 0.76 | EPHX2 (0.39) | PRNPHTTALDH1A1SCD5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980945-B2 | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021312-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIK4, GRM4, GRM1 | DYRK1A 2089/4885PRNP 1061/4885HTT 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.